Krystal BiotechKRYS
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 229
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
238% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 16
34% more call options, than puts
Call options by funds: $89.7M | Put options by funds: $67.2M
18% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 88
15% more funds holding
Funds holding: 242 [Q2] → 278 (+36) [Q3]
4.93% less ownership
Funds ownership: 102.83% [Q2] → 97.9% (-4.93%) [Q3]
5% less capital invested
Capital invested by funds: $5.39B [Q2] → $5.12B (-$273M) [Q3]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$206
39%
upside
Avg. target
$213
44%
upside
High target
$221
49%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Chardan Capital Geulah Livshits 8% 1-year accuracy 4 / 49 met price target | 43%upside $212 | Buy Maintained | 18 Dec 2024 |
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 117 / 398 met price target | 49%upside $221 | Buy Reiterated | 18 Dec 2024 |
Citigroup Yigal Nochomovitz 24% 1-year accuracy 11 / 45 met price target | 39%upside $206 | Neutral Maintained | 5 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value.
Positive
Seeking Alpha
3 weeks ago
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is projected to double earnings by 2025. With imminent EU and Japanese market expansion, Krystal seems poised to outperform analyst's expectations for growth.
Positive
Zacks Investment Research
1 month ago
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today initial clinical results from its ongoing KYANITE-1 study evaluating inhaled KB707 in patients with solid tumors of the lung. KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer (NSCLC), where an objective response rate (ORR) of 27% and disease control rate (DCR) of 73% were observed as of data cut-off on December 6, 2024.
Negative
Zacks Investment Research
1 month ago
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company's Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues.
Positive
Zacks Investment Research
1 month ago
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech to Present at Upcoming Investor Conferences
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.
Positive
Zacks Investment Research
2 months ago
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
Charts implemented using Lightweight Charts™